BROMFENAC

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H12BrNO3
Molecular Weight	334.165
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=C(CC(O)=O)C=CC=C1C(=O)C2=CC=C(Br)C=C2

InChI

InChIKey=ZBPLOVFIXSTCRZ-UHFFFAOYSA-N

InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula	C15H12BrNO3
Molecular Weight	334.165
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203168s000lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/bromfenac-ophthlamic-solution.html | http://www.rxlist.com/xibrom-drug.htm

Bromfenac is a topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia and vision blurred.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24796327	Inhibitor 8504		5.56 nM [IC50]
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24796327	Inhibitor 8504		7.45 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Ocular pain 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203168s000lbl.pdf	Primary		Approved 8583	PROLENSA Approved Use Bromfenac Ophthalmic Solution, 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction (1). Launch Date 2013
Postoperative inflammation 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203168s000lbl.pdf	Primary		Approved 8583	PROLENSA Approved Use Bromfenac ophthalmic solution (0.07%) is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Launch Date 2013

C_max

Value	Dose	Co-administered	Analyte	Population
58.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19049295	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:		BROMFENAC aqueous humor	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
313.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19049295	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:		BROMFENAC aqueous humor	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19049295	1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered:		BROMFENAC aqueous humor	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.2% OTHER GOV https://www.ema.europa.eu/en/documents/assessment-report/yellox-epar-public-assessment-report_en.pdf	unknown, unknown		BROMFENAC plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.09 % 2 times / day steady, ophthalmic Recommended Dose: 0.09 %, 2 times / day Route: ophthalmic Route: steady Dose: 0.09 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17720085	unhealthy, 20 years Health Status: unhealthy Age Group: 20 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/17720085	Disc. AE: Corneal melt... AEs leading to discontinuation/dose reduction: Corneal melt (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17720085
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/	unhealthy, 23.7 years Health Status: unhealthy Age Group: 23.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/	Other AEs: Headache, Nausea... Other AEs: Headache (1 patient) Nausea (1 patient) Dizziness (2 patients) Drowsiness (1 patient) Vomiting (1 patient) Hypotension (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/
25 mg 4 times / day steady, oral Recommended Dose: 25 mg, 4 times / day Route: oral Route: steady Dose: 25 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10492497	unhealthy, 60 years Health Status: unhealthy Age Group: 60 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/10492497	Disc. AE: Hepatitis fulminant... AEs leading to discontinuation/dose reduction: Hepatitis fulminant (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10492497
0.1 % single, ophthalmic Highest studied dose Dose: 0.1 % Route: ophthalmic Route: single Dose: 0.1 % Sources: https://pubmed.ncbi.nlm.nih.gov/19049295	unhealthy, 72.2 years (range: 24–95 years) Health Status: unhealthy Age Group: 72.2 years (range: 24–95 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19049295	Sources: https://pubmed.ncbi.nlm.nih.gov/19049295

AEs

AE	Significance	Dose	Population
Corneal melt	1 patient Disc. AE	0.09 % 2 times / day steady, ophthalmic Recommended Dose: 0.09 %, 2 times / day Route: ophthalmic Route: steady Dose: 0.09 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17720085	unhealthy, 20 years Health Status: unhealthy Age Group: 20 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/17720085
Drowsiness	1 patient	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/	unhealthy, 23.7 years Health Status: unhealthy Age Group: 23.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/
Headache	1 patient	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/	unhealthy, 23.7 years Health Status: unhealthy Age Group: 23.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/
Hypotension	1 patient	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/	unhealthy, 23.7 years Health Status: unhealthy Age Group: 23.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/
Nausea	1 patient	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/	unhealthy, 23.7 years Health Status: unhealthy Age Group: 23.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/
Vomiting	1 patient	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/	unhealthy, 23.7 years Health Status: unhealthy Age Group: 23.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/
Dizziness	2 patients	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/	unhealthy, 23.7 years Health Status: unhealthy Age Group: 23.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9690243/
Hepatitis fulminant	grade 5, 1 patient Disc. AE	25 mg 4 times / day steady, oral Recommended Dose: 25 mg, 4 times / day Route: oral Route: steady Dose: 25 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10492497	unhealthy, 60 years Health Status: unhealthy Age Group: 60 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/10492497

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	substrate 1193 inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 1079 CYP2A6 879 CYP1A2 2153 CYP2E1 1060 BSEP 550 MRP3 246 OATP1B3 961 MRP2 499 CYP2C19 2057 UGT1A1 246 MRP4 290	UGT2B7 456 UGT1A4 399 CYP2C8 810 OAT2 125 CYP2C19 1119 OATP1B1 503	rCYP 6

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625245#sid=103293849	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625246#sid=103293849	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625247#sid=103293849	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625248#sid=103293849	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625249#sid=103293849	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625250#sid=103293849	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625251#sid=103293849	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23750830/	no [IC50 >100 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23750830/	no [IC50 >100 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23750830/	no [IC50 >100 uM]
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23750830/	no [IC50 >100 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
rCYP 6	inducer 1966 Sources: https://www.pmda.go.jp/drugs/2000/g000304/24ctdp_1-305.pdf#page=128 Page: 128.0	no
UGT1A1 303	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23750830/	weak [IC50 77 uM]

Drug as victim

Target	Modality	Activity
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31815452/	yes
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31815452/	yes
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31815452/	yes
OAT2 125	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30135178/	yes
OATP1B1 503	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30135178/	yes
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31815452/	yes
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31815452/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625171#sid=103293849

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-071612	http://www.3bsc.com/index/pro_info.php?id=112687
AA Blocks	AA01EAYD	https://www.aablocks.com/goods/Goods/detail?id=AA01EAYD
Aaron Chemicals	AR01EBQ5	http://www.aaronchem.com/91714-93-1
abcr GmbH	AB479725	http://www.abcr.de/shop/en/AB479725
AbMole Bioscience	M2471	http://www.abmole.com/products/bromfenac-sodium.html
Acadechem	ACDS-067861	http://www.acadechemical.com/product/142560
Acorn PharmaTech	ACN-046782	http://www.acornpharmatech.com/
Adooq BioScience	A13244	https://www.adooq.com/bromfenac-sodium.html
AEchem Scientific Corp., USA	AE1-002733	http://www.aechemsc.com/info_products/AE1-002733.php
AHH Chemical co.,ltd	MT-02309	http://www.ahhchemical.com/product/MT-02309.html
AHH Chemical co.,ltd	MT-48752	http://www.ahhchemical.com/product/MT-48752.html
AK Scientific, Inc. (AKSCI)	2285AH	http://www.aksci.com/item_detail.php?cat=2285AH
Alfa Chemistry	91714-93-1	https://www.alfa-chemistry.com/bromfenac-sodium-cas-91714-93-1-item-109704.htm
Alfa Chemistry	ACM91714931	https://www.alfa-chemistry.com/bromfenac-sodium-cas-91714-93-1-item-109704.htm
Alfa Chemistry	AP91714931	https://reagents.alfa-chemistry.com/product/bromfenac-sodium-cas-91714-93-1-18539.html
Ambeed	A142956	https://www.ambeed.com/products/91714-93-1.html
Angel Pharmatech	AG308412	http://www.angelpharmatech.com/91714-93-1.html
ApexBio Technology	B1684	http://www.apexbt.com/bromfenac-sodium.html
Ark Pharm	AK601232	http://www.arkpharminc.com/products/91714-93-1.html
Aurora Fine Chemicals LLC	A17.911.578	http://online.aurorafinechemicals.com/info?ID=A17.911.578
AvaChem Scientific	2601	http://www.avachem.com/productSearch.asp?2601
BioChemPartner	BCP05811	http://www.biochempartner.com/91714-93-1-BCP05811
BioCrick	BCC4641	http://www.biocrick.com/Bromfenac-Sodium-BCC4641.html
BioSynth	J-004372	https://www.biosynth.com/en/products/all-products/products/J-004372.html
BioSynth	Q-200752	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-200752.html
BLD Pharm	BD69762	http://www.bldpharm.com/products/91714-93-1.html
BOC Sciences	91714-93-1	https://www.bocsci.com/bromfenac-sodium-cas-91714-93-1-item-100549.html
Boerchem	BC238440	http://www.boerchem.com/?product_38608.html
Boroncore	BC005156	http://www.boroncore.com/91714-93-1.html
ChemMol	30107437	http://www.chemmol.com/chemmol/30107437.html
ChemMol	30113928	http://www.chemmol.com/chemmol/30113928.html
ChemMol	44005322	http://www.chemmol.com/chemmol/44005322.html
ChemShuttle	159933	http://www.chemshuttle.com/catalogsearch/result/?q=120638-55-3&cat=
Chemspace	CSSB00016998065	https://chem-space.com/CSSB00016998065
Clearsynth	CS-O-06165	https://www.clearsynth.com/en/CSO06165.html
CSNpharm	CSN18760	https://www.csnpharm.com/products/bromfenac-sodium.html
eNovation Chemicals	D572919	https://www.enovationchem.com/ProductDetails.asp?ProductID=D572919
eNovation Chemicals	D634813	https://www.enovationchem.com/ProductDetails.asp?ProductID=D634813
eNovation Chemicals	D673682	https://www.enovationchem.com/ProductDetails.asp?ProductID=D673682
eNovation Chemicals	D767265	https://www.enovationchem.com/ProductDetails.asp?ProductID=D767265
Finetech	FT-0602701	http://www.finetechnology-ind.com/prod/detail/pub/91714-93-1.html
Finetech	FT-0660252	http://www.finetechnology-ind.com/prod/detail/pub/120638-55-3.html
Glentham Life Sciences	GL4176	http://www.glentham.com/products/product/GL4176/
Hairui	HR118924	http://www.hairuichem.com/en/product/120638-55-3.html
Molcore	MC511369	https://www.molcore.com/product/120638-55-3
Molcore	MC579839	https://www.molcore.com/product/91714-93-1
MolPort	MolPort-005-938-273	https://www.molport.com/shop/molecule-link/MolPort-005-938-273
MuseChem	A000173	https://www.musechem.com/product/A000173.html
MuseChem	I005027	https://www.musechem.com/product/I005027.html
Selleck Chemicals	S4248	http://www.selleckchem.com/products/bromfenac-sodium.html
Sigma-Aldrich	SML0289_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/sml0289?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S052204	http://www.sinfoobiotech.com/product/1055602
Synblock Inc	SB17363	http://www.synblock.com/product/91714-93-1.html
Synchem UG and Co KG	70546	http://www.synchem.de/chemical_Bromfenac%20Sodium.html
Yuhao Chemical	LX2757	http://www.chemyuhao.com/91714-93-1.html

PubMed

Title	Date	PubMed
Multiparametric assay using HepaRG cells for predicting drug-induced liver injury.	2015-07-02	25934330
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.	2014-01	24085192
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.	2012-08-20	22646477
Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?	2010-12-07	21128314
Ocular pharmacokinetics of 0.45% ketorolac tromethamine.	2010-12-01	21179226
Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes.	2010-12	19725815
Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections.	2010-10-28	21151329
Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database.	2010-10-25	20973999
Efficacy and safety of bromfenac for the treatment of corneal ulcer pain.	2010-10	20845001
Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines.	2010-09-20	20922036
Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery.	2010-09-07	20856594
Cytotoxicity of topical medications used for infection and inflammation control after cataract surgery in cultured corneal endothelial cells.	2010-09	20938094
Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data.	2010-05-17	20478034
NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema.	2010-02	20175270
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.	2009-12-02	19956587
Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins.	2009-12	19720731
Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.	2009-11-10	19898185
Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress.	2009-10-01	19810214
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.	2009-10	19934822
Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.	2009-10	19735215
Efficacy of ophthalmic nonsteroidal antiinflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacification.	2009-09	19683162
Concentration and dosing of ketorolac versus bromfenac.	2009-07	19545832
Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.	2009-06	19568702
Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis.	2009-06	19348602
Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery.	2009-05	19183412
Gateways to clinical trials.	2009-04	19536362
Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.	2009-03-03	19254390
Psychoactive medication and traffic safety.	2009-03	19440432
Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.	2009-03	19274523
Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK.	2009-02	19241773
Etiology and treatment of the inflammatory causes of cystoid macular edema.	2009	22096351
Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.	2009	19668566
Randomized controlled trial design in rheumatoid arthritis: the past decade.	2009	19232061
Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor.	2008-12	19049295
Off-label promotion, on-target sales.	2008-10-28	18959472
Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.	2008-09	18721711
Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells.	2008-08	18954319
24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits.	2008-08	18665811
Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.	2008-08	18655957
Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension.	2008-06	19668727
Topical ocular delivery of NSAIDs.	2008-06	18437583
Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).	2008-01-01	18165210
Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity.	2008-01	17549590
Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery.	2007-12	19668532
A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery.	2007-12	19668513
The systemic safety of bromfenac ophthalmic solution 0.09%.	2007-12	18001250
Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use.	2007-09	17720085
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.	2007-09	17720067
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.	2007-09	17445902
Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis.	2007	17440276

Patents

Sample Use Guides

In Vivo Use Guide

Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days postsurgery.

Route of Administration: Topical

In Vitro Use Guide

ARPE-19 cells treated with 4X and 2X clinical doses of bromfenac ophthalmic solution (BOS) showed mean CV of 16.95±3.04% (p<0.001), and 28.45±2.33% (p0.05). The ΔΨM was decreased and the caspase 3 /7 activity increased in ARPE-19 cells treated with all BOS concentrations when compared to untreated ARPE 19 controls (15.15±1.05). The ΔΨM of ARPE-19 cells were 2.74±0.36 (p<0.001), 2.35±0.33 (p<0.001), 2.63±0.20 (p<0.001), 5.30±0.18 (p<0.001) and 5.22±0.15 (p<0.001) for 4X, 2X, X, X/2 and X/4 concentrations respectively. The ROS activity was significantly increased for all BOS concentrations when compared to untreated control. Caspase 3/7 activity was significantly increased for all BOS concentrations.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:20:54 GMT 2025` Edited by `admin` on `Wed Apr 02 08:20:54 GMT 2025`
Record UNII	864P0921DW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BROMFENAC

Official Name

English

ISV-303

Preferred Name

English

bromfenac [INN]

Common Name

English

Bromfenac [WHO-DD]

Common Name

English

BROMFENAC [VANDF]

Common Name

English

BROMFENAC [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257